These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 14607764)

  • 21. Fondaparinux: a new synthetic and selective inhibitor of Factor Xa.
    Bauer KA
    Best Pract Res Clin Haematol; 2004 Mar; 17(1):89-104. PubMed ID: 15171960
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Heparins, low-molecular-weight heparins, and pentasaccharides.
    Dinwoodey DL; Ansell JE
    Clin Geriatr Med; 2006 Feb; 22(1):1-15, vii. PubMed ID: 16377464
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pentasaccharides. The new anticoagulants.
    Abdel-Razeq H
    Saudi Med J; 2004 Aug; 25(8):983-90. PubMed ID: 15322584
    [TBL] [Abstract][Full Text] [Related]  

  • 24. From heparins to factor Xa inhibitors and beyond.
    Alban S
    Eur J Clin Invest; 2005 Mar; 35 Suppl 1():12-20. PubMed ID: 15701143
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The use of low-molecular-weight heparins in pregnancy--how safe are they?
    Deruelle P; Coulon C
    Curr Opin Obstet Gynecol; 2007 Dec; 19(6):573-7. PubMed ID: 18007136
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Minimising the risk of heparin-induced osteoporosis during pregnancy.
    Hawkins D; Evans J
    Expert Opin Drug Saf; 2005 May; 4(3):583-90. PubMed ID: 15934862
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The use of unfractionated heparin and low molecular weight heparins in pregnancy.
    Casele HL
    Clin Obstet Gynecol; 2006 Dec; 49(4):895-905. PubMed ID: 17082684
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The present and future of heparin, low molecular weight heparins, pentasaccharide, and hirudin for venous thromboembolism and acute coronary syndromes.
    Haas S
    Semin Vasc Med; 2003 May; 3(2):139-46. PubMed ID: 15199477
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immediate type hypersensitivity to low molecular weight heparins and tolerance of unfractioned heparin and fondaparinux.
    Harr T; Scherer K; Tsakiris DA; Bircher AJ
    Allergy; 2006 Jun; 61(6):787-8. PubMed ID: 16677252
    [No Abstract]   [Full Text] [Related]  

  • 30. Bemiparin: second-generation, low-molecular-weight heparin for treatment and prophylaxis of venous thromboembolism.
    Martínez-González J; Vila L; Rodríguez C
    Expert Rev Cardiovasc Ther; 2008 Jul; 6(6):793-802. PubMed ID: 18570617
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Successful pregnancy outcome in women with bad obstetric history and recurrent fetal loss due to thrombophilia: effect of unfractionated heparin and low-molecular weight heparin.
    Ghosh K; Shetty S; Vora S; Salvi V
    Clin Appl Thromb Hemost; 2008 Apr; 14(2):174-9. PubMed ID: 18160603
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials.
    van Doormaal FF; Raskob GE; Davidson BL; Decousus H; Gallus A; Lensing AW; Piovella F; Prins MH; Büller HR
    Thromb Haemost; 2009 Apr; 101(4):762-9. PubMed ID: 19350123
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fondaparinux: a synthetic heparin pentasaccharide as a new antithrombotic agent.
    Walenga JM; Jeske WP; Samama MM; Frapaise FX; Bick RL; Fareed J
    Expert Opin Investig Drugs; 2002 Mar; 11(3):397-407. PubMed ID: 11866668
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and efficacy of lower-dose unfractionated heparin for prophylaxis of deep vein thrombosis and pulmonary embolism in an Asian population.
    Ugaki H; Enomoto T; Fujiwara K; Kimura T; Kawasaki T
    Blood Coagul Fibrinolysis; 2008 Sep; 19(6):585-9. PubMed ID: 18685443
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The pharmacoeconomics of deep vein thrombosis treatment.
    Shorr AF
    Am J Med; 2007 Oct; 120(10 Suppl 2):S35-41. PubMed ID: 17916458
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fondaparinux and the management of heparin-induced thrombocytopenia: the journey continues.
    Blackmer AB; Oertel MD; Valgus JM
    Ann Pharmacother; 2009 Oct; 43(10):1636-46. PubMed ID: 19737996
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fondaparinux as a novel therapeutic alternative in a patient with heparin allergy.
    Maetzke J; Hinrichs R; Staib G; Scharffetter-Kochanek K
    Allergy; 2004 Feb; 59(2):237-8. PubMed ID: 14763948
    [No Abstract]   [Full Text] [Related]  

  • 38. Heparin-induced thrombocytopenia: a review.
    Girolami B; Girolami A
    Semin Thromb Hemost; 2006 Nov; 32(8):803-9. PubMed ID: 17171593
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Skin reactions due to low molecular weight heparin in pregnancy: a strategic dilemma.
    Verdonkschot AE; Vasmel WL; Middeldorp S; van der Schoot JT
    Arch Gynecol Obstet; 2005 Feb; 271(2):163-5. PubMed ID: 15112083
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Unfractionated heparin, low molecular weight heparins, and pentasaccharide: basic mechanism of actions, pharmacology, and clinical use.
    Bick RL; Frenkel EP; Walenga J; Fareed J; Hoppensteadt DA
    Hematol Oncol Clin North Am; 2005 Feb; 19(1):1-51, v. PubMed ID: 15639107
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.